ARGENICA THERAPEUTICS LIMITED (AGN)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

AGN

AGN - ARGENICA THERAPEUTICS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.32

17 Sep
2025

0.010

OPEN

$0.31

3.23%

HIGH

$0.33

1,047,255

LOW

$0.28

OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . ARX . AVH . BIO . BOT . CSL . CUV . DXB . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS

- No Record -

HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20212022202320242025
EPS Basic xxxxxxxxxxxx-5.6
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxx5.6
Net Operating Cash Flow xxxxxxxxxxxx-5.7 M
Net Profit Margin xxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20212022202320242025
Return on Capital Employed xxxxxxxxxxxx-67.68 %
Return on Invested Capital xxxxxxxxxxxx-67.68 %
Return on Assets xxxxxxxxxxxx-52.31 %
Return on Equity xxxxxxxxxxxx-67.68 %
Return on Total Capital xxxxxxxxxxxx-102.85 %
Free Cash Flow ex dividends xxxxxxxxxxxx-5.7 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20212022202320242025
Short-Term Debt xxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx11 M
Price To Book Value xxxxxxxxxxxx13.49

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20212022202320242025
Capex xxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx11 M
Research & Development xxxxxxxxxxxx8 M
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

0
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Petra Capital

11/09/2025

1

Buy

$0.63

96.88%

Petra Capital notes Argenica Therapeutics' phase 2 stroke trial results fell short of the lofty market expectation that it would benefit across the entire stroke patient population. The trial only showed meaningful benefits in a pre-specified high-risk subgroup.

The broker argues the result is still clinically meaningful and de-risks the drug's development. However, it also means delays to the development and commercial timelines.

The company will now do a full analysis of the data before the end of 2025, and the broker has included a phase 2b trial in the model, ahead of phase 3. 

FY27-28 net profit forecasts downgraded, but FY29 upgraded, along with an upgrade to FY26.

Buy. Target cut to $0.63 from $1.24. 

FORECAST
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.50 cents.
Petra Capital forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -6.60 cents.
Access Extra Coverage Research History >

AGN STOCK CHART

FNArena News on AGN

1
Australian Broker Call *Extra* Edition – Sep 11, 2025

Sep 11 2025 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Sep 09, 2025

Sep 09 2025 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – Aug 18, 2025

Aug 18 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Aug 07, 2025

Aug 07 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Jun 12, 2025

Jun 12 2025 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia
2
Renewed Momentum For CSL Shares

Jul 22 2025 - Technicals
3
Treasure Chest: CSL Not A One-Trick Pony

Jul 14 2025 - Treasure Chest
4
The Enigma Surrounding Clinuvel

Jul 03 2025 - Small Caps
5
Rudi’s View: CSL & NextDC

May 08 2025 - Rudi's View
6
Behring Margin Outlook Still Main Game For CSL

Feb 13 2025 - Australia
7
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
8
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
9
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
10
CSL Shares Breaking Free

Jul 23 2024 - Technicals